TRVI trevitherapeutics.com: Enterprise Value to EBITDA Ratio
Trevi Therapeutics (TRVI) is developing innovative antitussive agents currently undergoing clinical trials. Tracking the company's EV/EBITDA valuation trend on GURU.Markets, we note that the value 0.00 describes the current enterprise value. The strategy is based on the launch of Haduvio for the treatment of pruritus; however, the risk of regulatory rejection and the need for capital create uncertainty for the biopharmaceutical startup's development.
Analytical breakdowns for trevitherapeutics.com (TRVI)
- current price and projected stock value:
- company stock capitalization data:
- business book valuation details:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Trevi Therapeutics|TRVI - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Trevi Therapeutics, Inc.|TRVI - Aggregate Debt Obligations|Debts to Book Capitalization Trevi Corp|TRVI - Long-Term Debt|Company Short-Term Debt Trevi Therapeutics|Quick Ratio trevitherapeutics.com
- financial results and valuation multiples details:
TRVI - Net Profit|Expected Profit Trevi Therapeutics|TRVI - Market Cap to Net Income|Forward P/E Multiple Trevi Therapeutics|TRVI - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Trevi Corp|TRVI - Operating profit EBITDA|Net earnings per share for the last 12 months Trevi Therapeutics|TRVI - Earnings per share for the last four quarters|Quarterly EPS earnings growth trevitherapeutics.com|TRVI - Expected net earnings per share growth this year|Earnings growth forecast for next year Trevi Therapeutics
- sales volume and revenue indicators:
Summary company analysis:Trevi Pharma TRVI
The EV/EBITDA ratio compares the total value of assets and net debt to operating profit, allowing an investor to determine the degree of business undervaluation relative to market peers. When analyzing the historical EV/EBITDA ratio of the business, one should evaluate the capitalization potential of Trevi Therapeutics (TRVI) through future sales of Haduvio to patients with chronic cough and itch whose therapy is covered by medical insurers.
Competitor analysis
EV/EBITDA Multiple BIIB (Biogen Corp)|Neurocrine Corp (NBIX) - Company Value to EBITDA|RGC: Enterprise Value to EBITDA Ratio|AXSM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACAD: EV/EBITDA Multiple|XENE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio VKTX|SUPN: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|Enterprise Value to Operating Income Before Depreciation Ratio DNLI|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|Business Value to Operating Income Before Depreciation BHVN|Amylyx - EV/EBITDA Multiple|Company Value to EBITDA Praxis Corp|Anavex Life Sciences (AVXL) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ceribell.com - Business Value to Operating Income Before Depreciation|PRTA (Prothena Corporation plc) - EV/EBITDA Multiple|EV/EBITDA Multiple Alector Therapeutics|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Annexon Inc. (ANNX)|OMER: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NGNE (Neurogene Inc.)|acimmune.com (ACIU) - Company Value to EBITDA|VYGR: Enterprise Value to EBITDA Ratio|NMRA - EV/EBITDA Multiple|SCLX (Scilex Holding Co.) - Enterprise Value to EBITDA Ratio|TVGN: Enterprise Value to Operating Income Before Depreciation Ratio|ACOG (Alpha Cognition Inc) - EV/EBITDA Multiple|cogrx.com (CGTX) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple IKT|Enterprise Value to EBITDA Ratio Cassava Sciences Inc SAVA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Assertio ASRT|Total Company Value to Operating Income Before Depreciation Ratio Coya Therapeutics Inc (COYA)|VTGN: Enterprise Value to EBITDA Ratio|Ovid Therapeutics Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|Acumen Pharmaceuticals, Inc. (ABOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CervoMed, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio ATHE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|EV/EBITDA Multiple PEPG|Total Company Value to Operating Income Before Depreciation Ratio jupiterneurosciences.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|ANVS: Enterprise Value to Operating Income Before Depreciation|Grace Tx - EV/EBITDA Multiple|Company Value to EBITDA Firefly Neuro|KLTO (anewmeds.com) - Enterprise Value to EBITDA Ratio|NeuroSense Therapeutics Ltd. (NRSN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|MTVA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT - Company Value to EBITDA|Passage Bio - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio NEUP (Neuphoria Therapeutics, Inc.)|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ATHA (Athira Pharma Inc)|ADXN: EV/EBITDA Multiple|Company Value to EBITDA Alzamend Neuro (ALZN)|Enterprise Value to EBITDA Ratio CYCN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PTIX|EV/EBITDA Multiple KTTA|Total Company Value to Operating Income Before Depreciation Ratio cortigent.com|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|CARA: Enterprise Value to EBITDA Ratio|chromocell.com - Enterprise Value to Operating Income Before Depreciation Ratio|ELYM: EV/EBITDA Multiple|Intra-Cellular Therapies, Inc. - Business Value to Operating Income Before Depreciation|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Company Value to EBITDA Marinus Pharma MRNS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAGE (Sage Therapeutics)|EV/EBITDA Multiple Synaptogenix Inc. SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA cerevel.com (CERE)
